Foamix to Host Key Opinion Leader Luncheon for Investors Focused on Dermatology, With a Focus on Acne and Rosacea

REHOVOT, Israel, and BRIDGEWATER, New Jersey, Nov. 28, 2016  /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will host a Key Opinion Leader luncheon for investors to discuss novel approaches to dermatology, with a focus on acne and rosacea, at 12:00pm Eastern Time on Friday, December 2, 2016, at the Lotte New York Palace Hotel.

The meeting will feature keynote presentations by key opinion leaders Guy Webster, MD, PhD, from Thomas Jefferson University, and Linda Stein Gold, MD, from the Henry Ford Health System, who will provide an overview of the acne and rosacea markets and discuss current and novel approaches to therapy.

Members of the Foamix executive management team will provide an overview of the programs in the Company's clinical pipeline, including FMX101, a novel minocycline foam for the treatment of moderate-to-severe acne, and FMX103 for the treatment of moderate-to-severe rosacea.

The luncheon event is intended for institutional investors and analysts only.  Please RSVP in advance if you plan to attend, as space is limited.  To reserve a spot, please contact LifeSci Advisors, LLC at [email protected] or call +1 212 915 2567.

A live webcast of the event, with slides, will be available at http://lifesci.rampard.com/20161202/reg.jsp and within the Investors section of the Company's website at www.foamixpharma.com.

Guy Webster, MD, PhD is a Clinical Professor of Dermatology at Thomas Jefferson University in Philadelphia, PA.  Dr. Webster is the author of over 150 publications, focusing mostly on inflammatory and infectious skin diseases. Until 2005, he was Professor and Vice Chairman in the Department of Dermatology of Jefferson Medical College where he also directed the clinical trials unit in the evaluation of therapeutics in dermatology.  Dr. Webster is the founding president of the American Acne and Rosacea Society and a Fellow of the Pennsylvania Academy of Dermatology and of the American Academy of Dermatology. He is also a member of the Society for Investigative Dermatology.  He is on the editorial boards of Journal of the American Academy of Dermatology, Dermatology Online Journal, Clinics in Dermatology, and Skin Therapy Letter. Dr. Webster was named to America's Best Doctors, 2004-2008, and his most recent book, Acne and Its Therapy, was published in 2007.

Linda Stein Gold, MD, is Director of Dermatology Clinical Research at Henry Ford Health System in Detroit, Michigan, as well as Division Head of Dermatology at Henry Ford Health System in West Bloomfield, Michigan. Dr. Stein Gold earned her undergraduate degree at the Wharton School of the University of Pennsylvania and her medical degree from the University of Pennsylvania School of Medicine.  She completed her residency in dermatology at Henry Ford Hospital in Detroit. Dr. Stein Gold is very active in clinical research on a variety of dermatologic conditions, including the treatment of chronic plaque-type psoriasis, actinic keratosis, atopic dermatitis, acne vulgaris, seborrheic dermatitis, and rosacea.  She has been on the medical board of the National Acne and Rosacea Society and the National Psoriasis Foundation Medical Board. She is a member of the Board of Directors of the American Academy of Dermatology.

Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.

Our clinical stage product candidates include our novel minocycline foam FMX101 for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.

We expect to release topline results from our Phase 3 trials of FMX101 during the first half of 2017.  We further expect to commence a Phase 3 program for FMX103 in 2017, following a meeting with the FDA to review the results of the recent Phase 2 trial.

In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare, Merz, Allergan and Mylan.

For more information, please visit www.foamixpharma.com.

Forward Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions, expectations, forecasts, beliefs or intentions related to financial results, commercial results, timing and results of clinical trials and U.S. FDA and other regulatory agencies authorizations. Forward-looking statements are based on our current knowledge and our present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of various factors including, but not limited to, unexpected delays, excess costs or unfavorable results of clinical trials, delays or denial in the U.S. FDA approval process, additional competition in the acne market, denial of reimbursement by third party payors or inability to raise additional capital. We discuss many of these risks in greater detail under the heading "Risk Factors" in our most recent Annual Report on Form 20-F (File No. 161477078) filed on March 7, 2016, and elsewhere in that Annual Report. Any forward-looking statements that may be made herein speak only as of the date of this release and Foamix undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Contact:                                                         US Investor Relations
Dorit Hayon                                                     Michael Rice   
Foamix Pharmaceuticals Ltd.                            LifeSci Advisors, LLC   
+972-8-9316233                                               +1-646-597-6979    
[email protected]                                    [email protected]

Logo: http://photos.prnewswire.com/prnh/20160906/404614LOGO

SOURCE Foamix Pharmaceuticals Ltd.

Related Links

http://lifesci.rampard.com/20161202/reg.jsp